BOULDER, CO / ACCESSWIRE / January 25, 2023 / Sonoma Pharma (Formerly Known As Oculus Innovative Sciences, Inc. )   (NASDAQ: SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including dermatology, eye, oral and nasal care, plus wound care, today announced that Microcyn ® Rx products have received a Distribution and Pricing Agreement (DAPA) for distribution by the Defense Logistics Agency (DLA).

The DAPA enables our partner, EMC Pharma, to enter into submission agreements for Microcyn® Rx products with federal customers. The U. S. government is the world’s largest purchaser of good and services. Approximately half of ELECTRONIC COUNTER MEASURE (ECM) Pharma’s customers are Oughout. S. government entities, including VA hospitals, the Division of Defense, the Federal Bureau of Prisons, as well because state plus local prison systems. EMC Pharma is a 100% minority-owned and a certified Minority Business Enterprise (MBE).

The DAPA approval process was a coordinated effort by Sonoma and EMC Pharma and resulted in obtaining DAPA # SP0200-22-H-0034 for Sonoma’s Microcyn Rx products which includes wound treatment, prescription dermatology products, Celacyn ® and Levicyn ® , plus prescription eye care Acuicyn ® .

“This is the major step that will allow us to sell Microcyn technology products into the federal supply chain. We have already seen interest from federal government networks with regard to these products and are excited to use our experience working with government customers in order to distribute Microcyn, ” said Eric Bailey, CEO and President associated with EMC Pharma.

“We are proud to work along with partners like EMC who have built a substantial business selling in to the numerous departments of the U. S. authorities, and we are excited to introduce the efficacy and safety of our own Microcyn technology products in order to these federal customers, ” said Amy Trombly, CEO of Sonoma. She continued, “sales to the U. S government through EMC Pharma represent a new distribution channel for Sonoma increasing the range of clients and regions we sell to. inch

About EMC Pharma, LLC

EMC Pharma, LLC will be a specialty pharmaceutical company committed to bringing innovative, cost effective medications to its stakeholders. ELECTRONIC COUNTER MEASURE (ECM) Pharma is usually a pharmaceutical manufacturing plus distribution organization focused on sales, marketing and distribution of prescription pharmaceuticals within a full spectrum of therapeutic areas and dosage forms. EMC Pharma leverages the global network of developers and manufacturing partners to create an expanding portfolio associated with pharmaceutical items commercialized for the US market. Further information about EMC Pharma can be found at .

About Sonoma Pharmaceuticals, Incorporation.

Sonoma Pharmaceuticals is definitely a global healthcare leader for building and generating stabilized hypochlorous acid (HOCl) products for any wide variety of programs, including wound care, vision care, nose care, dental care, plus dermatological conditions. The company’s products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl) show it in order to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma’s stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin, and oxygenates the cells in the area treated, assisting the particular body in its natural healing process. The particular company’s products are sold either directly or via partners in 55 countries worldwide plus the business actively seeks new submission partners. The company’s principal office is within Boulder, Colorado, with production operations in Guadalajara, Mexico. European advertising and sales are headquartered in Roermond, Netherlands. More information can be found at . For partnership opportunities, please contact [email protected] com .

Forward-Looking Statements

Except regarding historical info herein, matters set forth within this press release are forward-looking within the meaning of the “safe harbor” provisions associated with the Private Securities Litigation Reform Act of 1995, including statements about the particular commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “company”). These forward-looking statements are usually identified simply by the make use of words such since “continue, ” “develop” plus “expand, inch among others. Forward-looking statements in this pr release are subject to certain risks and uncertainties inherent in the carrier’s business that could cause actual results to vary, including such risks that regulatory clinical plus guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company’s patents and patent apps may become challenged, invalidated or circumvented by its competitors, the available marketplace for that industry’s products will not end up being as large as expected, the particular company’s products will not really be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company’s cash needs, fund further development, as well because uncertainties relative to the COVID-19 pandemic and economic development, varying product formulations and a multitude of diverse regulating and marketing and advertising requirements in different countries plus municipalities, and other risks detailed from time to period within the carrier’s filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking claims, except since required by law.

Sonoma Pharmaceuticals™, Microcyn ® , Celacyn ® , Levicyn ® , and Acuicyn ® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the particular property associated with their respective owners.

Media and Investor Contact:

Sonoma Pharmaceuticals, Incorporation.
[email protected] com

SOURCE: Sonoma Pharmaceuticals, Inc.

View source version on accesswire. com:

Leave a Reply

Your email address will not be published. Required fields are marked *